Characterization of a mGluR5 Knockout Rat Model with Hallmarks of Fragile X Syndrome.
autism spectrum disorders (ASDs)
extracellular matrix
machine learning
microglia
neurodevelopmental disorders
neuroinflammation
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
25 Aug 2022
25 Aug 2022
Historique:
received:
30
06
2022
revised:
17
08
2022
accepted:
18
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
The number of reported cases of neurodevelopmental disorders has increased significantly in the last few decades, but the etiology of these diseases remains poorly understood. There is evidence of a fundamental link between genetic abnormalities and symptoms of autism spectrum disorders (ASDs), and the most common monogenetic inheritable form of ASDs is Fragile X Syndrome (FXS). Previous studies indicate that FXS is linked to glutamate signaling regulation by the G-protein-coupled metabotropic glutamate receptor 5 (mGluR5), which has been shown to have a regulatory role in neuroinflammation. We characterized the effect of knocking out mGluR5 in an organism known to have complex cognitive functions-the rat. The heterozygous phenotype is the most clinically relevant; therefore, we performed analysis in heterozygous pups. We showed developmental abnormalities in heterozygous mGluR5 knockout rats, as well as a significant increase in chemokine (C-X-C motif) ligand 1 (CXCL) expression, a hallmark indicator of early onset inflammation. We quantified an increase in microglial density in the knockout pups and quantified morphological phenotypes representative of greater reactivity in the male vs. female and postnatal day 28 heterozygous pups compared to postnatal day 14 heterozygous pups. In response to injury, reactive microglia release matrix metalloproteases, contribute to extracellular matrix (ECM) breakdown, and are responsible for eradicating cellular and molecular debris. In our study, the changes in microglial density and reactivity correlated with abnormalities in the mRNA expression levels of ECM proteins and with the density of perineuronal nets. We saw atypical neuropsychiatric behavior in open field and elevated plus tests in heterozygous pups compared to wild-type litter and age-matched controls. These results demonstrate the pathological potential of the mGluR5 knockout in rats and further support the presence of neuroinflammatory roots in ASDs.
Identifiants
pubmed: 36143345
pii: life12091308
doi: 10.3390/life12091308
pmc: PMC9504063
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Burroughs Wellcome Fund
ID : Career Award at Scientific Interfaces
Références
J Pharmacol Exp Ther. 2005 Apr;313(1):395-402
pubmed: 15590770
Biochem Biophys Res Commun. 2006 Feb 17;340(3):776-83
pubmed: 16380085
Nat Protoc. 2021 Feb;16(2):754-774
pubmed: 33424024
J Neuroinflammation. 2014 Oct 25;11:182
pubmed: 25343964
FEBS J. 2016 Sep;283(18):3438-56
pubmed: 27444540
J Biol Chem. 2012 Feb 17;287(8):5412-25
pubmed: 22179607
Trends Genet. 2009 Jul;25(7):308-16
pubmed: 19556021
Nature. 2011 Nov 23;480(7375):63-8
pubmed: 22113615
Neurobiol Dis. 2016 Oct;94:116-28
pubmed: 27326668
Neurosci Biobehav Rev. 2014 Jan;38:160-72
pubmed: 24300694
Mol Psychiatry. 2002;7(3):311-6
pubmed: 11920158
Methods Mol Biol. 2019;1916:99-103
pubmed: 30535687
Cell Mol Life Sci. 2001 Nov;58(12-13):1842-56
pubmed: 11766883
Blood. 2013 Jun 13;121(24):4930-7
pubmed: 23645836
Neurosci Biobehav Rev. 2015 May;52:172-7
pubmed: 25704074
Eur J Neurosci. 2003 May;17(10):2106-18
pubmed: 12786977
Front Cell Dev Biol. 2014 Aug 28;2:45
pubmed: 25364752
Neurosci Lett. 2015 Nov 16;609:159-64
pubmed: 26483320
Brain Sci. 2019 Jan 12;9(1):
pubmed: 30642066
MMWR Surveill Summ. 2012 Mar 30;61(3):1-19
pubmed: 22456193
Nat Protoc. 2007;2(2):322-8
pubmed: 17406592
J Biomol Screen. 2013 Dec;18(10):1260-9
pubmed: 24088371
PeerJ. 2014 Jun 19;2:e453
pubmed: 25024921
Neurochem Res. 2015 Jun;40(6):1121-32
pubmed: 25846008
Mol Pharmacol. 2003 Dec;64(6):1295-308
pubmed: 14645659
J Neurosci. 2013 Jul 17;33(29):11863-77
pubmed: 23864676
JAMA. 2018 Jan 2;319(1):81-82
pubmed: 29297068
J Med Genet. 2009 Feb;46(2):94-102
pubmed: 18835858
PLoS One. 2011 Feb 17;6(2):e16715
pubmed: 21379579
Anal Bioanal Chem. 2017 Jan;409(2):379-394
pubmed: 27601046
Proc Natl Acad Sci U S A. 1989 Oct;86(19):7437-41
pubmed: 2477841
Trends Neurosci. 2004 Jul;27(7):370-7
pubmed: 15219735
Prog Neurobiol. 2013 Jul-Aug;106-107:1-16
pubmed: 23583307
Neurotherapeutics. 2015 Jul;12(3):521-33
pubmed: 26036957
Biochem Soc Trans. 2019 Dec 20;47(6):1651-1660
pubmed: 31845742
Brain Behav Immun. 2010 Aug;24(6):898-902
pubmed: 20102735
Curr Opin Investig Drugs. 2009 May;10(5):463-73
pubmed: 19431079
Brain Dev. 2020 Feb;42(2):113-120
pubmed: 31785985
J Vis Exp. 2015 Feb 06;(96):e52434
pubmed: 25742564
Brain Behav Immun. 2015 Oct;49:197-205
pubmed: 26052099
Front Cell Neurosci. 2019 Oct 25;13:472
pubmed: 31708746
Am J Physiol Regul Integr Comp Physiol. 2007 Aug;293(2):R581-9
pubmed: 17507437
Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20101-6
pubmed: 23169655
Sci Adv. 2019 Jan 23;5(1):eaav0394
pubmed: 30746473
Front Cell Neurosci. 2015 Jul 29;9:280
pubmed: 26283917
Biochem J. 2001 Nov 1;359(Pt 3):465-84
pubmed: 11672421
Am J Hum Genet. 2001 Aug;69(2):351-60
pubmed: 11443541
Psychopharmacology (Berl). 2014 Mar;231(6):1237-50
pubmed: 24173622
Nat Rev Neurosci. 2019 Aug;20(8):451-465
pubmed: 31263252
Sci Rep. 2017 Aug 30;7(1):9998
pubmed: 28855570
J Neurosci. 2013 Nov 13;33(46):18234-41
pubmed: 24227732
Intractable Rare Dis Res. 2016 Aug;5(3):145-57
pubmed: 27672537
J Cell Sci. 2000 Dec;113 Pt 23:4319-30
pubmed: 11069776
Sci Rep. 2019 Sep 26;9(1):13939
pubmed: 31558805
Int J Biochem Cell Biol. 2012 May;44(5):690-3
pubmed: 22297263
Mol Chem Neuropathol. 1997 Jun;31(2):97-118
pubmed: 9376025